Physician profile
Marifi Cabaluna
NPI 1831385665
$640.62
in general payments reported to CMS, 2019-2025
14 companies · $225 in 2025
The $225 reported for 2025 was more than what 77% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $181 · 2020: $35.21 · 2023: $57.06 · 2024: $143 · 2025: $225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $424.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $93.11 | 2024-2025 | |
| Tris Pharma INC | $74.19 | 2019-2020 | |
| Pfizer INC. | $68.33 | 2019-2023 | |
| Collegium Pharmaceutical, INC. | $67.62 | 2025 | Jornay Pm |
| Glaxosmithkline, LLC. | $64.22 | 2019-2025 | Rotarix, Bexsero |
| Cranial Technologies, INC | $56.71 | 2025 | Doc Band |
| Qiagen, LLC | $49.69 | 2024 | |
| Merck Sharp & Dohme LLC | $40.01 | 2019-2024 | Vaxneuvance, M-M-R II, Vaxelis |
| Sobi, INC | $34.40 | 2023 | |
| Genentech USA, INC. | $24.73 | 2019 | |
| Lnhc, INC | $22.52 | 2025 | Zelsuvmi |
| Kowa Pharmaceuticals America, INC. | $19.11 | 2025 | Zoryve |
| Alexion Pharmaceuticals, INC. | $15.00 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marifi Cabaluna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.